Psycheceutical is an innovative biotech company founded in 2020 in the United States. The company's slogan "Groundbreaking biotech solutions for safer, more effective psychedelic therapeutics" encapsulates its mission to revolutionize mental health treatments.
Specializing in Biotechnology and Pharmaceutical industries, Psycheceutical aims to overcome barriers in mental health care by leveraging patented delivery technologies to provide safe and effective psychedelic pharmaceutical medicines.
The company's recent investment of $1.30M in Post-IPO Debt, received on 01 June 2023, from Cantheon Capital underscores its potential and the confidence it commands from the investment community.
Psycheceutical's focus on advancing therapeutic solutions in the field of psychedelic medicine makes it a compelling and forward-thinking investment prospect in the biotech and pharmaceutical sectors.